Comment
These findings may be important in relation to hormone replacement therapy. Although it has not as yet been shown that lowering lipoprotein (a) concentrations reduces the risk of cardiovascular disease, by analogy with the results of other risk factor studies it seems likely that such a change will be beneficial. Previous work on lipoproteins has indicated that norethisterone may be unsuitable for long term prophylaxis against osteoporosis. Its effect on lipoprotein (a) concentrations, however, might, at least to some extent, offset its adverse effects on other lipoprotein risk factors.
Women who have not had hysterectomy who use postmenopausal oestrogens also receive a progestogen to protect them against endometrial cancer. Norethisterone is commonly used in combined preparations and there is concern that its effect on high density lipoproteins could partially negate the beneficial effects of oestrogen on the cardiovascular system. Our results suggest that the use of androgenic progestogens such as norethisterone may not be as deleterious as was previously feared. We suggest that in future hormone replacement studies lipoprotein (a) should be added to the lipoprotein risk markers currently monitored.
